Bank Of New York Mellon Corp Fennec Pharmaceuticals Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$6.21 - $8.68 $5,924 - $8,280	-954 Reduced 2.08%	44,912 $0
Q4 2020 Feb 09, 2021	SELL	$5.99 - $8.55 $16,526 - $23,589	-2,759 Reduced 5.67%	45,866 $0
Q3 2020 Nov 12, 2020	BUY	$5.19 - $10.17 $965 - $1,891	186 Added 0.38%	48,625 $0
Q2 2020 Aug 12, 2020	BUY	$5.43 - $9.39 $263,023 - $454,842	48,439 New	48,439 $0
Q2 2019 Aug 12, 2019	SELL	$3.3 - $5.09 $75,253 - $116,072	-22,804 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$5.37 - $8.39 $80 - $125	15 Added 0.07%	22,804 $145,000
Q2 2018 Aug 06, 2018	BUY	$10.05 - $14.33 $229,029 - $326,566	22,789 New	22,789 $237,000

14.7M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $165M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.